Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago.

The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline and ability to navigate challenges in the US market.